EMA Recommends Extension of Indications for Ribociclib to Include Use in Patients with Early Breast Cancer By Ogkologos - November 5, 2024 647 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with early breast cancer at high risk of recurrence Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Shortening Duration of Adjuvant Treatment from 6 to 3 Months Did... May 10, 2022 Adolescent and Young Adult Cancer Survivors Face More Co-morbidity in Later... September 30, 2020 EMA Recommends Extension of Indications for Avelumab December 17, 2020 Study Suggests Some Arthritis Drugs May Actually Stop the Spread of... November 26, 2019 Load more HOT NEWS Mapping Cancer Genomic Evolution Offers Insights into Tumor Development How to Cope With Taking Long-Term Medication Decorated Veteran Learns She Has Triple-Positive Breast Cancer While Pregnant with... How Does Smoking Increase Your Cancer Risk? An Expert Q&A
